Viva Biotech Highlights AI and Flow Chemistry Integration for Scalable Drug Synthesis

Apr 21, 2026
Viva Biotech discussed the integration of AI and flow chemistry in drug discovery during its recent webinar, showcasing advances in automated synthesis and scalable reaction workflows.

Viva Biotech hosted a webinar titled "AI x Flow Chemistry: From Bench to Business" to explore how artificial intelligence and flow chemistry are shaping modern synthesis workflows, announced in a press release. The event featured academic and industry experts discussing how these technologies are bridging the gap between molecular design and scalable execution.

Professor Jie Wu from the National University of Singapore presented advances in automated multistep synthesis, emphasizing the use of high speed circulation flow systems that combine batch and continuous processing. He introduced Chemical Recipe Files as a method to encode optimized synthesis protocols in a reproducible, machine executable format, supporting automated and scalable workflows.

Dr. Kejia Ding from Viva Biotech described how flow chemistry is being deployed across medicinal chemistry, process development, and manufacturing. Case studies included photochemical and difluoromethyl syntheses, where flow processing improved safety and scalability. A subsidiary, Langhua Pharma, demonstrated a continuous flow Curtius rearrangement that produced one thousand kilograms of material within two months.

The discussion highlighted how combining AI with automated synthesis and flow chemistry enables faster experimental validation of digitally designed molecules. Viva Biotech’s integrated platform connects discovery, synthesis, and manufacturing capabilities to support partners from early research through production.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.